April 19, 2017 / 12:11 PM / 3 months ago

BRIEF-DBP completes pre-clinical development of liver cancer drug candidate

1 Min Read

April 19 - DOUBLE BOND PHARMACEUTICAL INTERNATIONAL AB (PUBL):

* ANNOUNCED ON TUESDAY THAT PRE-CLINICAL TOXICOLOGICAL DEVELOPMENT OF SA-033 IS NOW COMPLETED

* Sa-033 Is Drug Candidate Against Cancers in Liver

* SA-033 IS NOVEL SELF-NAVIGATING FORMULATION BASED ON CANCER DRUG DOXORUBICIN

* RESULTS SHOW DAMAGE TO LIVER, KIDNEYS AND IMMUNE SYSTEM CAUSED BY DOXORUBICIN IN SA-033 ARE MUCH LESS PRONOUNCED COMPARED TO ORDINARY DOXORUBICIN FORM

Source text: bit.ly/2pfTM45

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below